A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration

Ophthalmology

Volumn 118, Issue 4, 2011, Pages 672-678

  Zhang, Ming ^a   Zhang, Junjun ^a   Yan, Mi ^a   Luo, Delun ^b   Zhu, Wenjin ^b   Kaiser, Peter K ^c   Yu, De Chao ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b Chengdu Kanghong Biotechnology Co Ltd   (China)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYBRID PROTEIN; KH 902; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

AGED; ARTICLE; CATARACT; CLINICAL ARTICLE; CONJUNCTIVAL HEMORRHAGE; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EXUDATIVE MACULAR DEGENERATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR PRESSURE; MALE; OPTICAL COHERENCE TOMOGRAPHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; SIDE EFFECT; SINGLE DRUG DOSE; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; ANGIOGENESIS INHIBITORS; CHOROIDAL NEOVASCULARIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAOCULAR PRESSURE; INTRAVITREAL INJECTIONS; MACULAR DEGENERATION; MALE; MAXIMUM TOLERATED DOSE; PROGNOSIS; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY;

EID: 79953328954     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2010.08.008     Document Type: Article

References (23)

1. Eye Disease Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-72.
2. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621-4.
3. Ferrara N. Vascular endothelial growth factor and regulation of angiogenesis. Recent Prog Horm Res 2000;55:15-35; discussion 35-6.
4. Ferrara N, Davis-Smith T. The biology of vascular endothelial growth factor. Endocr Rev 1997;18:4-25. (Pubitemid 27076453)
5. Miller JW. Vascular endothelial growth factor and ocular neovascularization. Am J Pathol 1997;151:13-23. (Pubitemid 27283952)
6. Gragoudas P, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;352:2805-16.
7. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31. (Pubitemid 44511557)
8. Nguyen QD, Shah SM, Browning DJ, et al. A phase I study of intravitreal vascular endothelial growth factor Trap-Eye in patients with neovascular age-related macular degeneration. Ophthalmology 2009;116:2141-8.
9. Do DV, Nguyen QD, Shah SM, et al. An exploratory study of the safety, tolerability and bioactivity of a single intravitreal injection of vascular endothelial growth factor Trap-Eye in patients with diabetic macular edema. Br J Ophthalmol 2009;93:144-9.
10. Carmeliet P, Moons L, Luttun A, et al. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001;7:575-83. (Pubitemid 32448325)
11. Rakic JM, Lambert V, Devy L, et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003;44:3186-93. (Pubitemid 36759791)
12. Shinkai A, Ito M, Anazawa H, et al. Mapping of the sites involved in ligand association and dissociation at the extracellular domain of the kinase insert domain-containing receptor for vascular endothelial growth factor. J Biol Chem 1998;273:31283-8. (Pubitemid 28533144)
13. Fuh G, Li B, Crowley C, Cunningham B, et al. Requirements for binding and signaling of the kinase domain receptor for vascular endothelial growth factor. J Biol Chem 1998;273:11197-204. (Pubitemid 28204970)
14. Holash J, Davis S, Papadopoulos N. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A 2002;99:11393-8. (Pubitemid 34920936)
15. Zhang M, Zhang JJ, Ya M, et al. Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choroidal neovascularization in monkeys. Mol Vision 2008;14:37-49.
16. Zhang M, Yu DC, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-Fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009;26:204-10.
17. Magdalena G, Krzystolik MD, Mehran A, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002;120:338-46.
18. Wang H, Shi J, Wang Q, et al. Assessment of pre-clinical immunogenicity of a new VEGF receptor Fc-fusion protein FP3 with ELISA and BIACORE. Cancer Immunol Immunother 2010;59:239-46.
19. Husain D, Kim I, Gauthier D, et al. Safety and efficacy of intravitreal injection of ranibizumab in combination with verteporfin PDT on experimental choroidal neovascularization in the monkey. Arch Ophthalmol 2005,123:509-16. (Pubitemid 40489924)
20. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-53. (Pubitemid 40797460)
21. Rosefeld PJ, Heier JS, Hantsbarger G, et al. Tolerability and efficacy of multiple escalating doses of ranibizumab (Lucentis) for neovascular age-related macular degeneration. Ophthalmology 2006;113:623-32.
22. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Ophthalmology 2005;112:1035-47.
23. Kaiser P, Blodi B, Shapiro H, et al. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114:1868-75.